Skip to main content
Top
Published in: BMC Surgery 1/2021

Open Access 01-12-2021 | Liver Transplantation | Research

Living donor liver transplantation for hepatocellular carcinoma beyond the Milan criteria: outcome of expanded criteria in tumor size

Authors: Hsin-Rou Liang, Chia-En Hsieh, Kuo-Hua Lin, Chih-Jan Ko, Yu-Ju Hung, Ya-Lan Hsu, Yao-Li Chen

Published in: BMC Surgery | Issue 1/2021

Login to get access

Abstract

Background

The Milan criteria are the universal standard of liver transplantation for hepatocellular carcinoma (HCC). Numerous expanded criteria have shown outcomes as good as the Milan criteria. In Taiwan, living donor liver transplant (LDLT) accounts for the majority of transplantations due to organ shortages.

Methods

We retrospectively enrolled 155 patients who underwent LDLT for HCC from July 2005 to June 2017 and were followed up for at least 2 years. Patients beyond the Milan criteria (n = 78) were grouped as recurrent or nonrecurrent, and we established new expanded criteria based on these data.

Results

Patients beyond the Milan criteria with recurrence (n = 31) had a significantly larger maximal tumor diameter (4.13 ± 1.96 cm versus 6.10 ± 3.41 cm, p = 0.006) and total tumor diameter (7.19 ± 4.13 cm versus 10.21 ± 5.01 cm, p = 0.005). Therefore, we established expanded criteria involving maximal tumor diameter ≤ 6 cm and total tumor diameter < 10 cm. The 5-year survival rate of patients who met these criteria (n = 134) was 77.3%, and the 5-year recurrence rate was 20.5%; both showed no significant differences from those of the Milan criteria. Under the expanded criteria, the pool of eligible recipients was 35% larger than that of the Milan criteria.

Conclusion

Currently, patients with HCC who undergo LDLT can achieve good outcomes even when they are beyond the Milan criteria. Under the new expanded criteria, patients can achieve outcomes as good as those with the Milan criteria and more patients can benefit.
Literature
1.
go back to reference Mazzaferro V, Egalia E, Gennari L. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med. 1996;334(11):369–99.CrossRef Mazzaferro V, Egalia E, Gennari L. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med. 1996;334(11):369–99.CrossRef
2.
go back to reference Yao FY, Ferrell L, Bass NM, Watson JJ, Bacchetti P, Venook A, et al. Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival. Hepatology. 2001;33(6):1394–403.CrossRef Yao FY, Ferrell L, Bass NM, Watson JJ, Bacchetti P, Venook A, et al. Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival. Hepatology. 2001;33(6):1394–403.CrossRef
3.
go back to reference Mazzaferro V, Llovet JM, Miceli R, Bhoori S, Schiavo M, Mariani L, et al. Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis. Lancet Oncol. 2009;10(1):35–43.CrossRef Mazzaferro V, Llovet JM, Miceli R, Bhoori S, Schiavo M, Mariani L, et al. Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis. Lancet Oncol. 2009;10(1):35–43.CrossRef
4.
go back to reference Lee HW, Suh KS. Advancements of liver transplantation for hepatocellular carcinoma in Korea. Jpn J Clin Oncol. 2017;47(2):93–100.CrossRef Lee HW, Suh KS. Advancements of liver transplantation for hepatocellular carcinoma in Korea. Jpn J Clin Oncol. 2017;47(2):93–100.CrossRef
5.
go back to reference Yao FY. Liver transplantation for hepatocellular carcinoma: beyond the Milan criteria. Am J Transplant. 2008;8(10):1982–9.CrossRef Yao FY. Liver transplantation for hepatocellular carcinoma: beyond the Milan criteria. Am J Transplant. 2008;8(10):1982–9.CrossRef
6.
go back to reference Choi HJ, Kim DG, Na GH, Han JH, Hong TH, You YK. Clinical outcome in patients with hepatocellular carcinoma after living-donor liver transplantation. World J Gastroenterol. 2013;19(29):4737–44.CrossRef Choi HJ, Kim DG, Na GH, Han JH, Hong TH, You YK. Clinical outcome in patients with hepatocellular carcinoma after living-donor liver transplantation. World J Gastroenterol. 2013;19(29):4737–44.CrossRef
7.
go back to reference Azoulay D, Audureau E, Bhangui P, Belghiti J, Boillot O, Andreani P, et al. Living or brain-dead donor liver transplantation for hepatocellular carcinoma: a multicenter, western, intent-to-treat cohort study. Ann Surg. 2017;266(6):1035–44.CrossRef Azoulay D, Audureau E, Bhangui P, Belghiti J, Boillot O, Andreani P, et al. Living or brain-dead donor liver transplantation for hepatocellular carcinoma: a multicenter, western, intent-to-treat cohort study. Ann Surg. 2017;266(6):1035–44.CrossRef
8.
go back to reference Yilmaz C, Karaca CA, Iakobadze Z, Farajov R, Kilic K, Doganay L, et al. Factors affecting recurrence and survival after liver transplantation for hepatocellular carcinoma. Transplant Proc. 2018;50(10):3571–6.CrossRef Yilmaz C, Karaca CA, Iakobadze Z, Farajov R, Kilic K, Doganay L, et al. Factors affecting recurrence and survival after liver transplantation for hepatocellular carcinoma. Transplant Proc. 2018;50(10):3571–6.CrossRef
9.
go back to reference Lencioni R, Llovet JM. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis. 2010;30(1):52–60.CrossRef Lencioni R, Llovet JM. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis. 2010;30(1):52–60.CrossRef
10.
go back to reference Goldaracena N, Gorgen A, Doyle A, Hansen BE, Tomiyama K, Zhang W, et al. Live donor liver transplantation for patients with hepatocellular carcinoma offers increased survival vs. deceased donation. J Hepatol. 2019;70(4):666–73.CrossRef Goldaracena N, Gorgen A, Doyle A, Hansen BE, Tomiyama K, Zhang W, et al. Live donor liver transplantation for patients with hepatocellular carcinoma offers increased survival vs. deceased donation. J Hepatol. 2019;70(4):666–73.CrossRef
11.
go back to reference Lee SG, Hwang S, Moon DB, Ahn CS, Kim KH, Sung KB, et al. Expanded indication criteria of living donor liver transplantation for hepatocellular carcinoma at one large-volume center. Liver Transplant. 2008;14(7):935–45.CrossRef Lee SG, Hwang S, Moon DB, Ahn CS, Kim KH, Sung KB, et al. Expanded indication criteria of living donor liver transplantation for hepatocellular carcinoma at one large-volume center. Liver Transplant. 2008;14(7):935–45.CrossRef
12.
go back to reference Uchiyama H, Itoh S, Yoshizumi T, Ikegami T, Harimoto N, Soejima Y, et al. Living donor liver transplantation for hepatocellular carcinoma: results of prospective patient selection by Kyushu University Criteria in 7 years. HPB (Oxford). 2017;19(12):1082–90.CrossRef Uchiyama H, Itoh S, Yoshizumi T, Ikegami T, Harimoto N, Soejima Y, et al. Living donor liver transplantation for hepatocellular carcinoma: results of prospective patient selection by Kyushu University Criteria in 7 years. HPB (Oxford). 2017;19(12):1082–90.CrossRef
13.
go back to reference Lee SD, Lee B, Kim SH, Joo J, Kim SK, Kim YK, et al. Proposal of new expanded selection criteria using total tumor size and (18)F-fluorodeoxyglucose—positron emission tomography/computed tomography for living donor liver transplantation in patients with hepatocellular carcinoma: the National Cancer Center Korea criteria. World J Transplant. 2016;6(2):411–22.CrossRef Lee SD, Lee B, Kim SH, Joo J, Kim SK, Kim YK, et al. Proposal of new expanded selection criteria using total tumor size and (18)F-fluorodeoxyglucose—positron emission tomography/computed tomography for living donor liver transplantation in patients with hepatocellular carcinoma: the National Cancer Center Korea criteria. World J Transplant. 2016;6(2):411–22.CrossRef
14.
go back to reference Shimamura T, Akamatsu N, Fujiyoshi M, Kawaguchi A, Morita S, Kawasaki S, et al. Expanded living-donor liver transplantation criteria for patients with hepatocellular carcinoma based on the Japanese nationwide survey: the 5-5-500 rule—a retrospective study. Transpl Int. 2019;32(4):356–68.CrossRef Shimamura T, Akamatsu N, Fujiyoshi M, Kawaguchi A, Morita S, Kawasaki S, et al. Expanded living-donor liver transplantation criteria for patients with hepatocellular carcinoma based on the Japanese nationwide survey: the 5-5-500 rule—a retrospective study. Transpl Int. 2019;32(4):356–68.CrossRef
15.
go back to reference Choi HJ, Kim DG, Na GH, Hong TH, You YK. Extended criteria for living donor liver transplantation in patients with advanced hepatocellular carcinoma. Transplant Proc. 2012;44(2):399–402.CrossRef Choi HJ, Kim DG, Na GH, Hong TH, You YK. Extended criteria for living donor liver transplantation in patients with advanced hepatocellular carcinoma. Transplant Proc. 2012;44(2):399–402.CrossRef
16.
go back to reference Todo S, Furukawa H, Tada M, Japanese Liver Transplantation Study G. Extending indication: role of living donor liver transplantation for hepatocellular carcinoma. Liver Transplant. 2007;13(11 Suppl 2):S48–54. Todo S, Furukawa H, Tada M, Japanese Liver Transplantation Study G. Extending indication: role of living donor liver transplantation for hepatocellular carcinoma. Liver Transplant. 2007;13(11 Suppl 2):S48–54.
17.
go back to reference Lee KW, Suh SW, Choi Y, Jeong J, Yi NJ, Kim H, et al. Macrovascular invasion is not an absolute contraindication for living donor liver transplantation. Liver Transplant. 2017;23(1):19–27.CrossRef Lee KW, Suh SW, Choi Y, Jeong J, Yi NJ, Kim H, et al. Macrovascular invasion is not an absolute contraindication for living donor liver transplantation. Liver Transplant. 2017;23(1):19–27.CrossRef
18.
go back to reference Chou CT, Chen RC, Lin WC, Ko CJ, Chen CB, Chen YL. Prediction of microvascular invasion of hepatocellular carcinoma: preoperative CT and histopathologic correlation. AJR Am J Roentgenol. 2014;203(3):W253–9.CrossRef Chou CT, Chen RC, Lin WC, Ko CJ, Chen CB, Chen YL. Prediction of microvascular invasion of hepatocellular carcinoma: preoperative CT and histopathologic correlation. AJR Am J Roentgenol. 2014;203(3):W253–9.CrossRef
19.
go back to reference Zhang W, Liu L, Wang P, Wang L, Liu L, Chen J, et al. Preoperative computed tomography and serum alpha-fetoprotein to predict microvascular invasion in hepatocellular carcinoma. Medicine (Baltimore). 2018;97(27):e11402. Zhang W, Liu L, Wang P, Wang L, Liu L, Chen J, et al. Preoperative computed tomography and serum alpha-fetoprotein to predict microvascular invasion in hepatocellular carcinoma. Medicine (Baltimore). 2018;97(27):e11402.
20.
go back to reference DuBay D, Sandroussi C, Sandhu L, Cleary S, Guba M, Cattral MS, et al. Liver transplantation for advanced hepatocellular carcinoma using poor tumor differentiation on biopsy as an exclusion criterion. Ann Surg. 2011;253(1):166–72.CrossRef DuBay D, Sandroussi C, Sandhu L, Cleary S, Guba M, Cattral MS, et al. Liver transplantation for advanced hepatocellular carcinoma using poor tumor differentiation on biopsy as an exclusion criterion. Ann Surg. 2011;253(1):166–72.CrossRef
21.
go back to reference Lin CC, Chen CL. Living donor liver transplantation for hepatocellular carcinoma achieves better outcomes. Hepatobiliary Surg Nutr. 2016;5(5):415–21.CrossRef Lin CC, Chen CL. Living donor liver transplantation for hepatocellular carcinoma achieves better outcomes. Hepatobiliary Surg Nutr. 2016;5(5):415–21.CrossRef
Metadata
Title
Living donor liver transplantation for hepatocellular carcinoma beyond the Milan criteria: outcome of expanded criteria in tumor size
Authors
Hsin-Rou Liang
Chia-En Hsieh
Kuo-Hua Lin
Chih-Jan Ko
Yu-Ju Hung
Ya-Lan Hsu
Yao-Li Chen
Publication date
01-12-2021
Publisher
BioMed Central
Published in
BMC Surgery / Issue 1/2021
Electronic ISSN: 1471-2482
DOI
https://doi.org/10.1186/s12893-021-01403-z

Other articles of this Issue 1/2021

BMC Surgery 1/2021 Go to the issue